LACTOLOGY FOUNDATION

Cisapride (ATC A03FA02) is a serotonin 5‑HT4 receptor agonist prokinetic that enhances upper gastrointestinal motility and is now withdrawn or severely restricted in many countries because of QT prolongation and serious ventricular arrhythmias. Available human milk data show very low transfer into breast milk and extremely low infant dose, so from a purely lactational-toxicological perspective, exposure via breastfeeding is minimal; however, its overall risk–benefit profile in the mother remains the main limiting factor.ncbi.nlm.nih+4

ATC class and pharmacological profile

Cisapride is classified in the ATC system as A03FA02, within “Drugs for functional gastrointestinal disorders”, subgroup “Propulsive agents (prokinetics)”. It is a gastroprokinetic agent that increases motility in the upper gastrointestinal tract without significant effect on gastric acid secretion.medpedia.framar+2

The drug acts primarily as a serotonin 5‑HT4 receptor agonist in the enteric nervous system, enhancing acetylcholine release from postganglionic cholinergic neurons. This mechanism accelerates gastric emptying, increases lower esophageal sphincter tone, and promotes coordinated peristalsis in the esophagus, stomach, and small intestine.wikipedia+1

Clinical indications (non‑lactation)

The main traditional indications of cisapride in humans were:

·        Gastroparesis (including diabetic gastroparesis).medpedia.framar+1

·        Gastroesophageal reflux disease (GERD), especially when standard therapies were insufficient.pubmed.ncbi.nlm.nih+1

In practice, cisapride was used for symptomatic relief of reflux and delayed gastric emptying, often as second‑line systemic therapy after non‑absorbed agents and H2 receptor antagonists. Because of safety concerns, its use is now restricted to carefully selected patients under strict monitoring or available only via special access programs in many jurisdictions.ema.europa+3

Regulatory status and safety concerns

Post‑marketing data revealed a significant risk of QT interval prolongation, torsades de pointes, and sudden cardiac death, particularly in patients with additional risk factors or concomitant QT‑prolonging drugs. As a result, cisapride has been withdrawn from the general market in many countries or its use has been limited to controlled settings with electrocardiographic monitoring.wikipedia+1

Regulatory guidance typically contraindicates cisapride in patients with known QT prolongation, significant electrolyte disturbances, pre‑existing cardiac disease, or concomitant use of potent CYP3A4 inhibitors or other QT‑prolonging medications. In the Bulgarian Medpedia entry, cisapride is presented as a prescription‑only medicine, with a brief contraindication for hypersensitivity and a recommendation for physician consultation regarding dosing.ema.europa+2

General toxicology (mother)

Cardiovascular toxicity is the principal concern and includes dose‑dependent QT prolongation and pro‑arrhythmic effects, especially in the presence of metabolic inhibition or structural heart disease. Pharmacokinetic interactions via CYP3A4 (for example with some macrolides, azole antifungals, and certain antidepressants) can markedly increase plasma cisapride levels and thereby raise arrhythmia risk.wikipedia+1

Non‑cardiac adverse effects include diarrhea, abdominal pain, and gastrointestinal discomfort due to increased motility, as well as occasional central nervous system symptoms such as headache. Cisapride can increase prolactin levels, which may theoretically influence lactation physiology, although clinical consequences are usually minor.e-lactation+2

Lactational pharmacokinetics

In a controlled study with ten puerperal women receiving cisapride 20 mg every 8 hours orally, steady state in breast milk was reached by day 3 of treatment. On day 4, mean cisapride concentrations were approximately 6.2 ± 1.3 ng/ml in milk versus 137 ± 8.1 ng/ml in maternal serum, indicating substantially lower levels in milk than in plasma.pubmed.ncbi.nlm.nih

Based on measured concentrations and standard milk intake assumptions, the suckling infant’s daily dose via breast milk was estimated to be 600–800 times lower than the usual therapeutic dose used in infants. These data indicate a very low relative infant dose, far below commonly used thresholds of concern for most medications.pubmed.ncbi.nlm.nih

Documented effects in breastfed infants

No adverse effects attributable to cisapride have been reported in breastfed infants whose mothers received therapeutic doses in available clinical series. The LactMed database concludes that, because of the low levels of cisapride in breast milk and the absence of reported toxicity, use in nursing mothers is acceptable when clinically required.ncbi.nlm.nih+1

E‑lactation similarly classifies cisapride as “usually compatible with breastfeeding”, noting excretion into milk in clinically non‑significant amounts and the lack of observed problems in exposed infants. Nonetheless, both sources emphasize that systemic cardiac risks for the mother, rather than lactational transfer, are the main limitation to its use.e-lactation+2

Comparative risk assessment in lactation

From a lactational-toxicological standpoint, cisapride’s risk to the breastfed infant appears low due to minimal transfer into milk and extremely small relative infant doses. The theoretical possibility of drug‑induced QT changes in the infant cannot be entirely excluded, but no such cases have been documented in the literature to date.ncbi.nlm.nih+2

Overall, the maternal cardiac risk profile (QT prolongation, arrhythmias, serious drug–drug interactions) dominates clinical decision‑making and often leads clinicians to select alternative prokinetics or reflux therapies during lactation. In GERD during lactation, guidelines generally favor agents with lower systemic exposure (such as alginates or sucralfate) and reserve systemic prokinetics for refractory cases.turkjgastroenterol+3

Use during breastfeeding: practical recommendations

When cisapride is considered for a lactating patient, its use should be restricted to situations where non‑systemic therapies and safer alternatives are ineffective and where the maternal benefit clearly outweighs the potential risks. Before initiation, maternal cardiac history, baseline ECG, and concomitant medications (particularly QT‑prolonging or CYP3A4‑inhibiting drugs) should be reviewed carefully to minimize maternal arrhythmia risk.cpdcentre+3

Given the low transfer into breast milk, routine interruption of breastfeeding is generally not required solely because of cisapride exposure when appropriate maternal monitoring is in place. However, some regulatory documents still advise avoiding breastfeeding during cisapride therapy, reflecting a precautionary approach driven by overall drug safety concerns rather than infant exposure via milk.e-lactation+3

Infant monitoring considerations

Although clinically significant infant exposure is unlikely, clinicians may choose to perform focused monitoring in certain settings, such as premature infants or those with known cardiac disease. Practical measures may include observation for feeding intolerance, vomiting, or unusual lethargy and, in high‑risk infants, consideration of baseline and follow‑up ECG if cumulative exposure is expected to be prolonged.pubmed.ncbi.nlm.nih+1

In settings where cisapride is used off‑label in infants for motility disorders, maternal treatment plus breastfeeding adds only a negligible additional dose relative to direct therapeutic dosing. In such cases, overall infant exposure is primarily governed by the direct pediatric dosing regimen rather than breast milk transfer.pubmed.ncbi.nlm.nih

Summary toxicological‑lactological classification (A03FA02)

Within your toxicological‑lactological framework, the A03FA02 class (cisapride) can be characterized as follows:

·        Nature of risk in lactation: low direct infant exposure via breast milk; primary concern is indirect (maternal cardiac toxicity, potential sudden maternal collapse).ema.europa+2

·        Evidence base: one pharmacokinetic study in lactating women with calculated infant dose 600–800‑fold below therapeutic levels, supported by absence of reported infant toxicity.ncbi.nlm.nih+1

·        Overall lactation compatibility: likely compatible from an infant‑exposure perspective, but use constrained by maternal safety and regulatory restrictions; alternative therapies are generally preferred when available.pubmed.ncbi.nlm.nih+3

For database tagging, a possible concise classification phrase could be: “Low infant exposure in milk; use limited by serious maternal cardiotoxicity and regulatory withdrawal in many countries.”